Clinical Trials Browser

Phase 2/3 × Interventional × Combined Modality Therapy × Clear all

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse